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Abstract: Exercise intolerance may be considered a hallmark in patients who suffer from heart failure
(HF) syndrome. Currently, there is enough scientific evidence regarding functional and structural de-
terioration of skeletal musculature in these patients. It is worth noting that muscle weakness appears
first in the respiratory muscles and then in the musculature of the limbs, which may be considered one
of the main causes of exercise intolerance. Functional deterioration and associated atrophy of these
respiratory muscles are related to an increased muscle metaboreflex leading to sympathetic–adrenal
system hyperactivity and increased pulmonary ventilation. This issue contributes to increased dys-
pnea and/or fatigue and decreased aerobic function. Consequently, respiratory muscle weakness
produces exercise limitations in these patients. In the present review, the key role that respiratory
muscle metaboloreceptors play in exercise intolerance is accurately addressed in patients who suf-
fer from HF. In conclusion, currently available scientific evidence seems to affirm that excessive
metaboreflex activity of respiratory musculature under HF is the main cause of exercise intolerance
and sympathetic–adrenal system hyperactivity. Inspiratory muscle training seems to be a useful
personalized medicine intervention to reduce respiratory muscle metaboreflex in order to increase
patients’ exercise tolerance under HF condition.
Keywords: exercise; heart failure; personalized medicine; pulmonary ventilation; respiratory muscles
1. Introduction
Heart failure (HF) has a high prevalence, affecting up to 23 million persons world-
wide [1]. This condition generates a high impact on functional activity, quality of life and
the aging process. In addition, it is a great economic burden for the healthcare system. HF is
presented as a multifactorial condition that affects neuro-humoral, structural, molecular
and cellular mechanisms, involving all these systems simultaneously in a network that im-
pairs physiological function. All complex and coordinated activities may generate ventricle
overload and greater sympathetic–adrenal activity, which may be associated with excessive
peripheral vasoconstriction leading to blood flow limitation of locomotor system muscles.
This circulation redistribution results in a complex clinical syndrome [2,3], which produces
an impaired filling of ventricles with or without a reduced fraction of ejection [4], associated
with a progressive deterioration of the musculoskeletal function [5–7]. Indeed, the pump-
ing HF to meet the metabolic tissue demands, together with the peripheral functional
impairment, may lead to dyspnea, exercise intolerance, fatigue and peripheral or lung
edema [1,4,5]. HF patients suffer from a great rate of mortality and morbidity, common
hospitalizations and poor quality of life [8]. This syndrome may be categorized into HF
including reduced fraction of ejection (HFrEF) and HF including preserved fraction of
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ejection (HFpEF). Subjects with ejection fractions ≥50% are diagnosed as patients with
HFpEF, while patients who present an ejection fraction from 41% to 49% are diagnosed
as patients with HFrEF [1]. In addition, the New York Heart Association (NYHA) created
a categorization for HF classes: class I, without symptoms or limitations; class II, slight
symptoms or limitations for physical activity; class III, important symptoms or limitations
for physical activity; and class IV, symptoms or limitations at resting state [9].
Exercise intolerance plays a primary role in HF patients linked to nonfavorable prog-
nosis [10]. HF patients suffer from an altered respiratory pattern as well as dyspnea with
physical activity [10,11]. In spite of the common HF sequelae, there is a lack of a clear asso-
ciation between exercise intolerance and cardiac functioning parameters, such as ejection
fraction, volume of the left ventricle and cardiac output [10]. Hemodynamic alterations
are considered key factors that produce HF symptoms secondary to heart ineffectiveness,
generating an increase in cardiac output and venous pressures of systemic and pulmonary
mechanisms. New evidence supports a muscular hypothesis suggesting skeletal muscle
deterioration as the main cause of HF symptoms [6,11–13]. Muscular weakness present
in HF patients occurs more commonly in inspiratory muscles than in the lower limb
muscles [11,14,15]. The atrophy of these skeletal muscles is produced due to decreased
cardiac output as well as tissue hypoxia processes, inflammation alterations, higher sys-
temic catabolism and longer immobilization periods [7]. These alterations are linked to
protein degradation, a higher presence of myokines and muscle fiber changes from slow-
twitch or type I fibers to fast-twitch or type II fibers [5,16]. Indeed, impaired oxidative
metabolism and early acidosis are produced due to a lower presence of mitochondria, de-
creased density of the mitochondrial ridges and reduced mitochondrial enzymatic activity
decreasing enzymes such as 3-hydroxyacyl-CoA dehydrogenase, succinate dehydrogenase
and citrate synthetase [16]. Consequently, these processes lead to muscular resistance
reduction, afferent reflexes or meta-reflex activation, as well as sustained and increased
sympathetic–adrenal activity [17,18]. Furthermore, ventilation pattern alterations pro-
duce greater dyspnea, higher fatigue and reduced aerobic capacity [5–7,16–18]. Therefore,
inspiratory muscle weakness has been associated with HF leading to potential adverse
effects [11,13]. Inspiratory muscle weakness is linked to greater muscle meta-reflex, playing
a key role in HF prognosis [19].
Muscular meta-reflex is a blood flow regulator mechanism for cardiac output, blood
pressure and regional distribution, and it involves chemical receptors of muscle parenchyma
activated by metabolites secondary to muscle contractile properties [20,21]. Afferent fibers
of muscle tissue involved in the meta-reflex consist of nonmyelinated group IV neurons,
including chemical sensitive receptors for metabolites secondary to skeletal muscle contrac-
tion [5,20–22]. Currently, there is a lack of scientific evidence to determine the specific kind
of metabolite that activates the muscle meta-reflex [23]. Nevertheless, potassium, lactic acid,
adenosine, diprotonated phosphate, arachidonic acid, prostaglandins, capsaicin and serotonin
have been suggested as possible specific metabolites that activate the muscle metaboreflex,
but not for adenosine and acidic pH [20,22,24,25]. These metabolic stimuli induced by muscle
contraction activate molecular receptors located at the terminal end of unmyelinated nerve
fibers, such as group IV fibers which are mainly metabolosensitive. Consequently, a spon-
taneous discharge of the muscle afferent fibers is projected through the input dorsal root of
the spinal cord and spreads to the dorsal horns of various spinal cord segments. Muscle
fiber inputs reach various integration levels. These reflexes do not seem to need activity of
the rostral brain, although supraspinal integration could coexist. In addition, the medulla is
considered the control area for cardiovascular responses under activation of the mechano-
metaboreflexes [5,26]. Efferent responses to the activation of muscular meta-reflexes may
comprise higher activity of sympathetic nerves constricting systemic vessels, as well as in-
creasing blood flow in contracted muscular fibers and provoking cardiac ionotropic responses
and chronotropic effects to produce greater output at the same time. Thus, muscle meta-
reflex generates sympathetic–adrenal responses, which increase blood pressure for exercise
performance, allowing blood flow and volume redistribution [20].
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According to the detailed process, respiratory muscle meta-reflex appears secondary
to fatigue during activity that produces metabolic subproduct accumulation, triggering
the activation of the receptors in unmyelinated type IV phrenic afferent fibers; project-
ing towards the centers of supraspinal brainstem regions implicated in the control of
somatosensory cortex, hypothalamus, cerebellum and cardiorespiratory centers; and conse-
quently provoking the meta-reflex activation of these muscles [20–22,27–31]. In addition,
these meta-reflexes activate a sympathetic response, leading to vasoconstriction at a periph-
eral level, blood flow reduction of skeletal muscular perfusion, fatigue increase induced
by exercise and redistribution of blood flow of respiratory muscles to maintain adequate
functioning. Current scientific evidence suggests that one of the main reasons why the
diaphragm suffers less vasoconstriction than the limb muscles is due to the fact that the
diaphragm presents fewer α1-adrenergic receptors, but more evidence is required to affirm
this statement [20,27,29,31–34]. The increased fatigue of skeletal muscle leads to intolerance
under exercise activity and reduced strength of the muscular system [27,29]. Furthermore,
respiratory muscle meta-reflex produces increased heart rates and blood pressure and
reduced blood flow in renal, mesenteric and limb arterial vessels, leading to reduced O2
diffusion to muscles [22,25,28].
Regarding patients who suffer from HF, muscle metaboreflex presents an exaggerated
activity due to key changes in skeletal muscle, leading to excessive afferent feedback to
group IV receptors. One of the main causes of such exaggerated activation is the histological
alteration of skeletal muscle fibers that indicates a change in the proportion of fiber type
and the expression of the chain isoform of heavy myosin. These myosin chains of type I
and gain of type IIx may provoke an increase in metabolic activity, a reduction of oxidative
capacity and an increase in group IV afferent activation. Thus, this leads to an increase
in vascular resistance at a systemic level, limiting cardiac output, stroke volume and O2
supply and generating impaired exercise capacity and peak VO2 in HF patients [35–38].
Inspiratory muscle weakness appears in approximately 50% of HF patients [30], con-
tributing to a worse prognosis for these patients [32]. The diagnosis of HF is performed
when the maximum inspiratory pressure (PImax) fraction is <70% with respect to the nor-
malized value based on a patient’s age and gender [11,39] or when PImax direct values are
≤60 cmH2O [40]. PImax seems to be linked to the perception of dyspnea for daily activity, be-
ing considered as a prognostic indicator for HF patients [30,33,41,42]. Dyspnea and fatigue
symptoms presented in HF patients may be partially due to respiratory muscle weak-
ness [11,29,30,43–46] associated with decreased respiratory muscle strength, which leads
to a higher PImax fraction for the respiration process. Thus, patients note a higher inten-
sity of dyspnea secondary to increased PImax fractions for this process [47]. In addition,
respiratory musculature weakness is linked to reduced tidal volume, which produces a
higher ratio of ventilation-dead space and increased ventilation–perfusion mismatch for
exercise activities performed by HF patients. Furthermore, increased correlations between
CO2 and ventilation are presented as the main prognostic indicators for these individu-
als [29,45–47]. In conclusion, inspiratory muscle weakness increases fatigue, promoting
early metaboloreceptor activation in respiratory muscles [32].
In addition, weakness of respiratory muscles may be associated with histological
alterations. Respiratory muscle biopsies carried out in HF patients showed a reduced
percentage in both type IIx muscle fibers and type IIa muscle fibers, as well as a greater pro-
portion of type I muscle fibers with respect to healthy controls [7,48–50]. These alterations
seem to differ from those presented in the skeletal musculature of limbs [7]. Although the
type I muscle fiber proportions seem to commonly increase in respiratory musculature,
respiratory muscle atrophy is presented in HF patients [29,39,50]. In addition, a greater
proportion of type I muscle fiber is linked to higher oxidative activity of enzymes under
HF conditions. All those alterations could be secondary to myogenic factors of regulation
associated with an increased effort for sustained ventilation. This adaptation process may
facilitate an increase in respiratory resistance, accompanied by a parallel reduction of
muscular power and maximum strength for these muscles [30,48].
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Considering other factors that modify respiratory functions in conjunction with in-
spiratory muscle weakness under HF condition, increased respiratory activity may be
presented secondary to respiratory musculature because it must function against higher
elastic and/or resistive loads [10]. Increased elastic load appears to be a consequence of
higher stiffness of the pulmonary tissue secondary to the intrathoracic space competition
between heart tissue and the lungs, such as the presence of congested pulmonary flow,
cardiomegaly, bronchial vascular flows and pulmonary interstitial edema. An increase in
resistive loads may lead to congestion of the lungs associated with limited expiratory flows
as well as sustained hyperventilation [10,11,29], resulting in higher blood flow and oxygen
requirements for respiratory muscles. HF seems to be accompanied by a limited response in
cardiac output under exercise activity, and thus the fatigue appears earlier [10]. In addition,
Yamada et al. [29] reported that HF patients who present respiratory muscle weakness
are likely to show functional capacity limitations in 6-min walking tests, regardless of
muscle weakness in the lower extremities or restrictive patterns of the respiratory system.
In addition, weakness of inspiratory musculature is linked to various NYHA functional
classes, with the greatest inspiratory forces found in individuals who suffer from class I HF
and the lowest inspiratory forces found in class IV HF patients [30,51].
Indeed, inspiratory muscle weakness together with increased breathing load may
facilitate the fatigue process of these muscles, producing early activation of metabolorecep-
tors of the respiratory musculature. This process causes exaggerated metaboreflex activity
in the respiratory muscles of HF patients. It should be noted that this increased activity
may also produce higher hyperventilation in these patients, since the afferents of group IV
neurons through dorsal horns of spinal cord neural structures reach respiratory centers of
the medulla, such as the rostral ventral cord, caudal ventro-lateral cord and solitary tractus
nucleus, generating an exacerbated fatigue of the respiratory muscles [10,32]. Furthermore,
muscle metaboreflex, in conjunction with weakness of these muscles, may be considered an
important activator of chemoreflex, through peripheral and/or central stimuli, under HF
condition. This provokes activation under a lower threshold, which leads to sustained
increases in sympathetic activity and causes adrenergic vasoconstrictions, as well as an
increase in right and/or left ventricular afterload. Thus, sympathetic hyperactivation is
considered an important mortality predictor in HF patients [32].
An interesting method used to investigate respiratory muscle fatigue and its conse-
quent activation of the metaboreflex in HF patients with exercise intolerance is the use of a
noninvasive mechanical ventilator to reduce the inspiratory muscle load [52–55]. In these
studies, the load reduction of these muscles increased blood flow of limbs, cardiac output,
muscle oxygen absorption (VO2), muscle oxygen diffusing capacity (DMO2) and exercise
tolerance and decreased the vascular resistance of limbs and sympathetic–adrenal system
activity. Respiratory muscle metaboreflex needs the limbs’ blood flow since the discharge
of the inspiratory muscles produces increased blood flow in the extremities and a reduction
of blood flow in the respiratory musculature [52–55]. Therefore, it seems that inspiratory
musculature training (IMT) could be presented as a useful therapy in order to decrease the
respiratory muscle metaboreflex, which could reduce fatigue of these muscles [56].
2. Material and Methods
2.1. Study Design
A study design of narrative review was used according to “Preferred Reporting
Items of Systematic Review & Meta-analyses (PRISMA)” guidelines [57]. The present
study was carried out in order to provide an update of available information of previous
systematic reviews considering the reduction of respiratory muscle metaboreflex by IMT
in HF patients [42,58], including various study types such as quasi-experimental studies
and clinical trials with publication dates before September 2020.
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2.2. Search Strategies
A database search was performed in September 2020. PubMed was the database used
for this search process. Used restrictions were experimental records providing full access
by the search strategy named as (“inspiratory muscle training” OR “respiratory muscle
training”) AND “heart failure” included in abstract and/or title of English and/or Spanish
language studies [56].
2.3. Study Selection
Inclusion selection criteria consisted of experimental records of different types, such as
clinical trials and/or quasi-experimental studies analyzing the effects of IMT on respiratory
muscle metaboreflex in HF patients. Exclusion criteria included nonexperimental research
studies and meta-analyses or systematic reviews that comprised patients with comor-
bidities in conjunction with IMT such as stroke, lung hypertension, Fontan circulation
and mitral valve pathologies, among other conditions, as well as all studies that did not
analyze IMT effects on respiratory muscle metaboreflex. All possible outcome measure-
ments analyzing IMT effects in an isolated way or in conjunction with other treatments on
metaboreflex of respiratory muscles were included in this review in order to update the
available information on HF patients [42,58].
2.4. Data Extraction Processes
Research features including sample sizes, demographic and social data, baseline out-
come measures, training protocols, detailed schedule, frequencies, intensities, IMT devices
and protocols were recorded and are detailed in Tables 1 and 2.
Data extraction included study citations, intervention groups, sample size, mean ±
standard deviation (SD), p-value to detail statistical significance and supplemental infor-
mation on measurement procedures; these results are detailed in Tables 1 and 2 following
the updated review studies [42,58].
3. Results and Discussion
3.1. Flow Chart
From 105 studies that were identified by search processes, 100 records were removed
according to exclusions and duplicates. Lastly, five records were selected for the narrative
synthesis, as shown in Figure 1.
3.2. IMT Effects on Metaboreflex in HF Patients
IMT is a training intervention using workloads for inspiration [42]. IMT may be
carried out utilizing three different devices such as inspiratory threshold, resistive load and
isocapnic hyperpnea devices. Firstly, IMT by inspiratory threshold device uses inspiratory
pressures to provoke the openness of a valve allowing air flows to pass for the inspiratory
process. Secondly, IMT by resistive load device uses several holes of different reduced
diameters which generate resistance for the inspiratory process. Thirdly, IMT by isocapnic
hyperpnea device uses an equipped laboratory of respiratory physiology to maintain a
ventilation level for volitional hyperpnea for 12 min while the CO2 is combined with the
inspiration air maintaining isocapnia status for the arterial blood flows [59].
Inspiratory muscle weakness presented in HF patients may be reversible. Therefore,
IMT is a useful intervention for improving the strength and/or resistance of inspiratory
musculature in HF patients [56,60].
Currently, a total of 30 papers have studied the IMT effects in HF patients [28,39,40,44,61–86].
From these 30 studies, only 5 studies [28,66,67,74,85] analyzed the IMT effects on respiratory
muscle metaboreflex. Four studies were randomized clinical trials [28,66,74,85] and one study
was a quasi-experimental study [67] (Table 1). Sample sizes were small for most of these studies.
All studies were performed in HFrEF patients [28,66,67,74,85]. IMT modality applied in two
studies was inspiratory training with threshold devices [67,74], and two studies applied resistive
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load devices [66,85]. Concretely, Moreno et al.’s [28] study provided the IMT intervention group
with the possibility to apply devices for resistive load or threshold (Table 2).
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Table 1. Characteristics of the studies.
Year and Author Group (n),Male/Femal Age (Years)
NYHA Class
(II/III) LVEF (%) PImax (cmH2O)
2008. Chiappa




IMT: 57 ± 11
C: 38 ± 12
IMT: 10/8
C: N/A
IMT: 24 ± 3
C: N/A
IMT: 60 ± 8





IMT: 53.4 ± 2.1
C: 57.3 ± 4
IMT: 9/5
C: 6/3
IMT: 28.9 ± 2.4
C: 28.6 ± 1.9
IMT: 78.5 ± 4.9
C: 84.6 ± 5.9
2012.
Mello et al. [74]
IMT: 15, 9/6
C: 12, 5/7
IMT: 54.3 ± 2
C: 53.3 ± 2
IMT: 15/0
C: 12/0
IMT: 33.6 ± 2.3
C: 37.6 ± 1.6
IMT: 56.1 ± 2.3





IMT: 61 ± 14
C: 60 ± 13
IMT: 6/7
C: 7/6
IMT: 35 ± 9
C: 37 ± 6
IMT: 60 ± 13
C: 60 ± 16
2020. Antunes




IMT: 55 ± 3
C: 57 ± 3




IMT: 31 ± 2
C: 25 ± 1
AET: 26 ± 2
IMT: 86 ± 9
C: 85 ± 8
AET: 87 ± 10
AET = aerobic exercise training; C = control group; IMT = inspiratory muscle training; LVEF = ejection fraction left ventricle; N/A = no
available data; NYHA = New York Heart As ociation; PIm x = maximum inspiratory pressure. * Qua i-experimental study.
Int. J. Environ. Res. Public Health 2021, 18, 1697 7 of 12
Table 2. Description of the interventions.
Year and




















IMT: 30 IMT: 7 4
Control group without intervention.
In the experimental group, the intensity














All sessions were supervised. In the
experimental group, the intensity was
readjusted in each session; in the control
group, it was fixed.
The session had six efforts at each level:
Level I: 60 s for rest in each
inspiration effort
Level II: 45 s for rest between series
Level III: 30 s for rest between series
Level IV: 15 s for rest between series
Level V: 10 s for rest between series
Level VI: 5 s for rest between series.
After level VI, rest for 5 s maintained up to
respiratory fatigue process.
2012.






3/day IMT: 7 13
Control group had usual care.
In the experimental group, the intensity









IMT: 30 min IMT: 6 8
Control group without intervention.
In the experimental group, the intensity














Control group without intervention.
In the experimental group, the intensity
was readjusted weekly and one session
weekly was supervised.
In the AET group, all sessions were
supervised. Sessions comprised 5 min for
stretching exercise, 40 min for cycling, 10
min for local strengthening exercise and 5
min for cooldown. Aerobic exercise was
performed under anaerobic thresholds up
to 10% under respiratory
compensation points.
AET = aerobic exercise training; C = control group; IMT = inspiratory musculature training; N/A = no available data; SMIP = sustained
maximum inspiratory pressure. * Quasi-experimental study.
Cardiac rehabilitation may be considered a comprehensive rehabilitation program
that improves functional capacities under HF condition. Currently, cardiac programs
for rehabilitation seem to be underutilized [87]. IMT intervention is a useful alternative
therapy that is suitable for the participation of HF patients. In addition, IMT may be
adequate for patients who are not candidates for cardiac programs for rehabilitation,
such as individuals unable to carry out exercises, so it is considered a useful personalized
medicine intervention [42,58]. Inspiratory muscle weakness presented in HF patients may
be reversible.
Regarding metaboreflex activity, five studies [28,66,67,74,85] detailed IMT effects on
respiratory muscle meta-reflexes; statistically significant improvements (p < 0.05) were
claimed in four of them, but such improvements were not found in the study performed by
Laoutaris et al. [66]. A total of three studies [67,74,85] analyzed IMT effects on blood flow
of limb muscles for rest and exercise activity. These studies reported improvements in this
parameter due to vascular resistance reduction in limbs, except for Laoutaris et al.’s [66]
study, which did not observe any statistically significant difference (p > 0.05) in the blood
flow of forearms between intervention groups, although the reactive hyperemic blood
flow of forearms showed statistically significant improvement (p < 0.05) due to IMT in-
Int. J. Environ. Res. Public Health 2021, 18, 1697 8 of 12
tervention. IMT produces statistically significant increases (p < 0.05) in ventilation loads
required in order to produce peripheral vasoconstrictions by the respiratory musculature
meta-reflexes. Such a fact could be explained by higher fatigue resistances in those muscles,
producing a reduction in metabolite accumulation that triggers activation of the meta-
reflexes [28,67,74,85]. Therefore, IMT may be linked to an inspiratory muscle release effect
by greater inspiratory muscle thickness, diaphragmatic muscular aerobic capacity and
strength. These effects were linked to a reduction of the accumulation of metabolites as
well as decreased peripheral vasoconstriction, leading to greater peripheral blood flows as
well as higher exercise tolerance [27,46,67]. Following the reported meta-reflexes reduction,
Mello et al. [74] detailed that IMT decreased muscular sympathetic activities, producing
an improvement of the vagal and sympathetic modulations for cardiovascular systems
under HF condition. In addition, the reduction of the sympathetic adrenal activity may be
explained as secondary to the chemo-reflex reduction due to IMT provoking an improve-
ment in oxygen saturation. Indeed, Moreno et al. [28] detailed how respiratory muscle
meta-reflexes were reduced by IMT intervention. In conclusion, an improvement in the
oxygen saturations for forearm and/or intercostal musculature was reported, improving
the muscles’ O2 diffusion. Thus, IMT may be a suitable intervention to decrease the inspi-
ratory musculature meta-reflexes under HF condition, which would be a key intervention
option for personalized medicine in HF patients.
3.3. Future Research and Limitations
Although statistical significance and data extraction were accurately detailed, method-
ological quality analyses, risks of bias, heterogeneity analysis and forest plots were not
included because confidence intervals were not detailed for all studies. Our study’s
records showed heterogeneity and did not permit us to perform systematic reviews and/or
meta-analyses. These issues justified this narrative review to detail the available scientific
evidence about IMT effects on respiratory muscle metaboreflex activity of HF patients.
Furthermore, the present narrative review included the available experimental records,
including clinical trials as quasi-experimental records that analyzed IMT effects on res-
piratory muscle metaboreflex in HF patients. Future research studies should perform
high-quality meta-analyses and systematic reviews following the PRISMA criteria [57] to
provide updated strong evidence about IMT effects on respiratory muscle metaboreflex in
HF patients [42,58].
It is worth noting that the accuracy of distinguishing between primary or muscular
and vascular induced HF or weakness may present some difficulties because the pro-
posed methods seem to be less suitable for this differential diagnosis, as discussed by
Guski et al. [88]. These authors proposed the use of specific antibodies to provide infor-
mation about the immunoreactivity of ischemia-damaged cardiomyocytes. In addition,
some future studies should consider virtual autopsy for HF prediction because this method
may offer additional benefits for digital tissue-based diagnosis, such as tissue or organ
dysfunctions and the HF patient’s prognosis [89].
4. Conclusions
Currently available scientific evidence seems to affirm that excessive metaboreflex
activity of respiratory musculature under HF condition is one of the main causes of exercise
intolerance and sympathetic–adrenal system hyperactivity. IMT seems to be a useful
personalized medicine intervention to reduce respiratory muscle metaboreflex in order to
improve exercise tolerance in HF patients.
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